Combining antidepressant therapies from the initiation of treatment: A paradigm shift for major depression

Journal of Clinical Psychiatry

Volumn 70, Issue 11, 2009, Pages 1493-1494

  Stahl, Stephen M ^a,b  

^a NEUROSCIENCE EDUCATION INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DESIPRAMINE; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; FOLIC ACID; HOMOCYSTEINE; HYPNOTIC AGENT; METHYLFOLATE; MIRTAZAPINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM;

CLINICAL PRACTICE; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INSOMNIA; MAJOR DEPRESSION; MENTAL DISEASE; MONOTHERAPY; POLYPHARMACY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RELAPSE; REMISSION; REVIEW; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FOLIC ACID; HUMANS; HYPNOTICS AND SEDATIVES; RECURRENCE; TETRAHYDROFOLATES; TREATMENT OUTCOME;

EID: 72849116866     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09bs05697blu     Document Type: Review

References (18)

1. Stahl SM. Stahl's Essential Psychopharmacocology. 3rd ed. New York: Cambridge University Press; 2008.
2. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom. 2006;75(3):139-153 PubMed doi:10.1159/000091771.
3. Stahl SM. Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 2009;14(2):71-73. PubMed
4. Van der Schyf CJ, Youdim MBH. Multifunctional drugs as neurotherapeutics. Neurotherapeutics. 2009;6(1):1-3 PubMed doi:10.1016/j.nurt.2008.11.001.
5. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics. 2009;6(1):53-77 PubMed doi:10.1016/j.nurt.2008.10.039.
6. Stahl SM. Mechanism of action of trazodone, a multifunctional drug. CNS Spectr. 2009;14(10):412-422.
7. Stahl SM. Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. CNS Spectr. 2008;13(12):1027-1038. PubMed
8. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55(3):296-300 PubMed doi:10.1016/j.biopsych.2003.08.007.
9. Blier P, Gobbi G, Turcotte JE, et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol. 2009;19(7):457-465 PubMed doi:10.1016/j.euroneuro.2009.01.015.
10. Blier P, Ward HE, Tremblay P, et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double blind randomized study. Presented at the American Psychiatric Association; May 20-25, 2006; Toronto, Ontario, Canada.
11. Godfrey PSA, Toone BK, Carney MW, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336(8712):392-395 PubMed doi:10.1016/0140-6736(90)91942-4.
12. Coppen A, Bailey J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord. 2000;60(2):121-130 PubMed doi:10.1016/S0165-0327(00)00153-1. (Pubitemid 30680129)
13. Resler G, Lavie R, Campos J, et al. Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes. Neuroimmunomodulation. 2008;15(3):145-152 PubMed doi:10.1159/000151527.
14. Stahl SM. Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressantaugmenting agent. CNS Spectr. 2007;12:739-744. PubMed
15. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006;59(11):1052-1060 PubMed doi:10.1016/j.biopsych.2006.01. 016. (Pubitemid 43849658)
16. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008;65(5):551-562 PubMed doi:10.1001/archpsyc. 65.5.551. (Pubitemid 351645051)
17. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009;29(3):222-230 PubMed doi:10.1097/JCP.0b013e3181a390ba.
18. Stahl SM. Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. Int J Neuropsychopharmacol. 2007;10(5):575-578 PubMed doi:10.1017/S1461145707008000.